Paul Horstmeier - Aug 5, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role
Chief Operating Officer
Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Aug 5, 2021
Transactions value $
-$429,606
Form type
4
Date filed
8/9/2021, 08:35 PM
Previous filing
Jul 8, 2021
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $170K +10.8K +9.5% $15.84 124K Aug 5, 2021 Direct
transaction HCAT Common Stock Sale -$306K -5.54K -4.47% $55.16 118K Aug 5, 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$177K -3.15K -2.66% $56.20 115K Aug 5, 2021 Direct F1, F3
transaction HCAT Common Stock Sale -$117K -2.06K -1.78% $56.93 113K Aug 5, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -10.8K -12.55% $0.00 74.9K Aug 5, 2021 Common Stock 10.8K $15.84 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F2 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.71 to $55.66, inclusive.
F3 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.74 to $56.69, inclusive.
F4 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $56.75 to $57.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) through (4).
F5 25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.